Video Programs

A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing response rates of almost 50% with 20% complete responses, and offers the advantage of reliable intravenous delivery despite logistical challenges of infusion center visits.

A panelist discusses how axatilimab demonstrated efficacy in a heavily pretreated patient population with predominantly severe chronic graft-vs-host disease (cGVHD) in the AGAVE-201 trial, with manageable adverse effects including infusion reactions and enzyme elevations that rarely required discontinuation of treatment.

Panelists discuss how most clinicians prefer ruxolitinib over ibrutinib as second-line therapy due to better tolerability

Panelists discuss how FDA-approved therapies such as ibrutinib, ruxolitinib, belumosudil, and axatilimab provide treatment options for steroid-refractory chronic graft-vs-host disease (cGVHD).

A panelist discusses how the CABINET trial showed significant progression-free survival benefits for cabozantinib compared with placebo (particularly in pancreatic neuroendocrine tumors (NETs), why progression-free survival (PFS) is a meaningful end point for NETs, and that safety findings revealed familiar adverse effects requiring dose reductions in about two-thirds of patients.

Panelists discuss how the CYTO-PV study provides compelling evidence for maintaining strict hematocrit control below 45% in polycythemia vera patients, demonstrating that even a 3% difference in hematocrit levels can lead to a fourfold increase in cardiovascular events and thrombosis risk while also emphasizing the independent importance of controlling white blood cell counts below 11 × 109/L to further reduce thrombotic complications.

A panelist discusses how the CABINET trial was a National Cancer Institute (NCI)–supported study conducted by the Alliance for Clinical Trials in Oncology that enrolled patients with well-differentiated grade 1 through 3 pancreatic or extrapancreatic neuroendocrine tumors who had progressed after somatostatin analogue therapy and at least 1 other FDA-approved therapy.

Panelists discuss how multiple pivotal clinical trials inform polycythemia vera management strategies, highlighting key findings from CYTO-PV (strict hematocrit control <45% reduces thrombosis risk fourfold), RESPONSE (ruxolitinib’s superiority over best available therapy for controlling both hematocrit and splenomegaly), MAJIC-PV (demonstrating improved event-free survival with ruxolitinib), and PROUD-PV/CONTINUATION-PV (showing ropeginterferon’s durable molecular responses compared with hydroxyurea’s diminishing effect over time).

Panelists discuss how JAK inhibitor therapy, while effective in treating myelofibrosis and other hematologic disorders, increases the risk of skin cancers, particularly non-melanoma skin cancers, and emphasize the importance of regular screening, patient education, and preventive measures to manage this risk.

Panelists discuss how prophylaxis against opportunistic infections is essential for patients on immunosuppressive therapy for chronic graft-vs-host disease (cGVHD).

Panelists discuss how specialists balance controlling chronic graft-vs-host disease (cGVHD) symptoms while minimizing steroid exposure when patients fail initial therapy.

A panelist discusses how axatilimab, a humanized IgG4 monoclonal antibody targeting CSF-1 receptors on monocytes and macrophages, showed promising results in the AGAVE-201 trial for treatment-resistant chronic graft-vs-host disease (cGVHD), with high response rates, durable responses, and tolerable adverse effects at the FDA-approved dose of 0.3 mg/kg every 2 weeks.

A panelist discusses how chronic graft-vs-host disease (cGVHD) is a common posttransplant complication with increasing incidence due to peripheral blood stem cell grafts, older patients, and more unrelated donor transplants, which can manifest in multiple organs and is typically treated with corticosteroids as first-line therapy.

Panelists discuss how managing advanced polycythemia vera requires tailored approaches beyond hydroxyurea when patients show resistance (persistent hematocrit >45%, elevated white blood cell counts, ongoing symptoms), with experts advocating for either second-line ruxolitinib for rapid symptom and hematologic control or interferons (particularly in younger patients), while emphasizing the importance of addressing modifiable cardiovascular risk factors like smoking cessation.

A panelist discusses how first-line treatment options for neuroendocrine tumors depend on tumor grade, disease extent, and symptoms, ranging from observation for asymptomatic cases to somatostatin analogues, chemotherapy, and the newly approved cabozantinib.

Panelists discuss how polycythemia vera treatment follows a risk-stratified approach, with all patients receiving daily aspirin and phlebotomies to maintain hematocrit below 45%, while high-risk patients (aged >60 years or history of thromboembolism) additionally require cytoreductive therapy with options including hydroxyurea, pegylated interferon alfa-2a, ropeginterferon alfa-2b, or second-line ruxolitinib, with treatment modifications based on response, tolerance, and disease progression.

A panelist discusses how neuroendocrine tumors are defined by World Health Organization (WHO) classification, graded based on Ki-67 proliferative index, diagnosed through imaging (often incidentally), and most commonly found in the small bowel, lungs, and pancreas.

Panelists discuss how important end points for evaluating new myelofibrosis therapies include overall survival, symptom improvement, splenic volume reduction, hematologic parameters, disease modification, safety, and patient-reported outcomes, all of which help assess the impact of treatment on both clinical outcomes and quality of life.

Panelists discuss how investigational therapies beyond Janus kinase (JAK) inhibition, including epigenetic modulation, telomerase inhibition, PI3K/AKT/mTOR pathway inhibition, immune modulation, TGF-β inhibition, and novel anti-fibrotic agents, are showing promise in improving efficacy and targeting different disease pathways in myelofibrosis.

Panelists discuss how steroid dosing for chronic graft-vs-host disease (cGVHD) typically starts at 0.5-1 mg/kg/day depending on severity, with careful tapering to avoid flares.

Panelists discuss how patient education and multidisciplinary involvement are critical for early detection of chronic graft-vs-host disease (cGVHD).

Panelists discuss how the MOMENTUM trial demonstrated momelotinib’s superiority over danazol in symptomatic anemic myelofibrosis patients, showing significant improvements in symptoms (the primary end point), meaningful spleen volume reduction (SVR25/SVR35), and anemia benefits, with experts noting that the inclusion of a washout period provided clearer evidence of momelotinib’s efficacy profile compared to the SIMPLIFY-2 trial.

Panelists discuss how second-line treatment decisions for myelofibrosis patients failing ruxolitinib can be guided by clinical trial data such as that from SIMPLIFY-2, whereas momelotinib offers comparable spleen control with superior anemia benefits and potential symptom improvement, although experts emphasize the importance of considering a patient’s specific failure pattern and setting appropriate expectations when switching therapies.

Panelists discuss how managing myelofibrosis patients with challenging cytopenias involves careful treatment selection, regular monitoring of blood counts, and tailored dose adjustments to balance disease control with the risks of exacerbating hematologic toxicities.

Panelists discuss how selecting and optimizing Janus kinase (JAK) inhibitor therapy in myelofibrosis involves personalizing treatment based on patient risk factors, comorbidities, and preferences while emphasizing regular monitoring to manage adverse effects and improve quality of life.

Panelists discuss how difficult-to-diagnose cases of chronic graft-vs-host disease (cGVHD) often include pulmonary involvement, gynecological manifestations, and neurological symptoms.

A panelist discusses how successful management of chronic graft-vs-host disease (cGVHD) requires a multifaceted approach that combines prompt recognition, strategic intervention, and comprehensive supportive care to optimize both disease control and quality of life for transplant survivors.